UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
A study by UC San Diego researchers and their colleagues has found that semaglutide slows down the accumulation of biological aging markers in the DNA of adults with HIV, pointing to the potential of GLP‑1 receptor agonists to help prevent age‑related diseases.
U.S. overdose death rates declined between 2023 and 2024, marking the first recorded drop in all four waves of the nation’s overdose crisis. However, overdose deaths involving stimulants without fentanyl, and xylazine-related deaths, continue to rise and racial disparities remain severe.
Robert Mancini, PharmD ’08, the Distinguished Alumnus of the Year for UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, brought advanced cancer care to Idaho, lead the nation’s oncology pharmacists as president of HOPA and trains the next generation of oncology pharmacists.
UC San Diego researchers discovered that blocking microRNA-25 reshapes the tumor immune environment and improves responses to cancer immunotherapy.
Researchers from UC San Diego have uncovered a new possibility for treating melanoma, and it's something we have in our bodies already.
A new AI model developed by UC San Diego researchers could make it possible to predict treatment response based only on a tumor's genetics.
The Atlantic, May 5
Becker’s Hospital Review, May 5
New York Post, May 4
New York Post, May 3
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
